A study for the treatment of patients with HIV-1 was a randomized, controlled, double-blind K study that compared the effectiveness of ritonavir-boosted darunavir (rbd), the drug currently used to treat HIV-1, with dorovirine, a newly developed drug. Of the 374 subjects taking ritonavir-boosted darunavir, 309 achieved a positive result. Of the 374 subjects taking dorovirine, 320 achieved a positive result. Complete parts (a) and (b). Identify the test statistic. Z = (Round to two decimal places as needed.) Identify the p-value. p-value = (Round to three decimal places as needed.) Since the p-value is the significance level of a = 0.01, the null hypothesis. There is evidence to support the claim that the percentage from the ritonavir-boosted darunavir group is the percentage from the dorovirineA study for the treatment of patients with HIV-1 was a randomized, controlled, double-blind K study that compared the effectiveness of ritonavir-boosted darunavir (rbd), the drug currently used to treat HIV-1, with dorovirine, a newly developed drug. Of the 374 subjects taking ritonavir-boosted darunavir, 309 achieved a positive result. Of the 374 subjects taking dorovirine, 320 achieved a positive result. Complete parts (a) and (b). a. Find the sample percentage of subjects who achieved a positive outcome in each group. The sample percentage of subjects who achieve a positive outcome with ritonavir-boosted darunavir is %. The sample percentage of subjects who achieve a positive outcome with dorovirine is % (Round to two decimal places as needed.) b. Perform a hypothesis test to test whether the proportion of patients who achieve a positive outcome with the current treatment (ritonavir-boosted darunavir) is less than the proportion of patients who achieve a positive outcome with the new treatment (dorovirine). Use a significance level of 0.01. Analyze the results and determine if dorovirine is a more effective treatment for HIV-1 than ritonavir-boosted darunavir. Consider population 1 to be the ritonavir-boosted darunavir with the proportion of positive outcomes p, and population 2 to be the dorovirine with the proportion of positive outcomes Ydarunavir group is the percentage Analyze the results. Is dorovirine a more effective treatment for HIV-1 than ritonavir-boosted darunavir? Why or why not? O A. No, although the decision of the test was to reject the null hypothesis of no difference, it cannot be concluded that one treatment is better than the other-it can only be concluded that they are different. O B. Yes, since the decision of the test was to fail to reject the null hypothesis of the proportion from the ritonavir-boosted darunavir group being greater than the proportion of the dorovirine group. O C. Yes, since the decision of the test was to reject the null hypothesis of no difference O D. No, since the decision of the test was to fail to reject the null hypothesis of no difference